Literature DB >> 21880854

Dexamethasone-induced cytokine changes associated with diminished disease severity in horses infected with Anaplasma phagocytophilum.

R S Davies1, J E Madigan, E Hodzic, D L Borjesson, J S Dumler.   

Abstract

Anaplasma phagocytophilum is the zoonotic cause of granulocytic anaplasmosis. We hypothesized that immune response, specifically gamma interferon (IFN-γ), plays a role in disease severity. To test this, horses were infected and IFNG expression was pharmacologically downregulated using corticosteroids. Eight horses were infected with A. phagocytophilum; 4 received dexamethasone on days 4 to 8 of infection. Clinical signs, hematologic parameters, and transcription of cytokine/chemokine genes were compared among treated and untreated horses. Infection was quantitated by msp2 real-time PCR and microscopy. As anticipated, there was significantly greater leukopenia, thrombocytopenia, and anemia in infected versus uninfected horses. The A. phagocytophilum load was higher for dexamethasone-treated horses. Dexamethasone reduced IFNG transcription by day 12 and IL-8 and IL-18 by days 7 to 9 and increased IL-4 on day 7. The ratio of IL-10 to IFNG was increased by dexamethasone on day 9. There were no hematologic differences between the infected horses. Dexamethasone suppression of proinflammatory response resulted in delayed infection-induced limb edema and decreased icterus, anorexia, and reluctance to move between days 6 and 9 and lower fever on day 7. These results underscore the utility of the equine model of granulocytic anaplasmosis and suggest that Th1 proinflammatory response plays a role in worsening disease severity and that disease severity can be decreased by modulating proinflammatory response. A role for Th1 response and macrophage activation in hematologic derangements elicited by A. phagocytophilum is not supported by these data and remains unproven.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880854      PMCID: PMC3209032          DOI: 10.1128/CVI.05034-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Quantitative evaluation of ehrlichial burden in horses after experimental transmission of human granulocytic Ehrlichia agent by intravenous inoculation with infected leukocytes and by infected ticks.

Authors:  N Pusterla; C M Leutenegger; J S Chae; H Lutz; R B Kimsey; J S Dumler; J E Madigan
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 2.  Transcriptional and post-transcriptional control of gene expression in inflammation.

Authors:  Michael Kracht; Jeremy Saklatvala
Journal:  Cytokine       Date:  2002-11-07       Impact factor: 3.861

3.  Serum cytokine responses during acute human granulocytic ehrlichiosis.

Authors:  J S Dumler; E R Trigiani; J S Bakken; M E Aguero-Rosenfeld; G P Wormser
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  Infection of mice with the agent of human granulocytic ehrlichiosis after different routes of inoculation.

Authors:  E Hodzic; S Feng; D Fish; C M Leutenegger; K J Freet; S W Barthold
Journal:  J Infect Dis       Date:  2001-05-17       Impact factor: 5.226

5.  The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines.

Authors:  M B Klein; S Hu; C C Chao; J L Goodman
Journal:  J Infect Dis       Date:  2000-06-29       Impact factor: 5.226

6.  Gamma interferon dominates the murine cytokine response to the agent of human granulocytic ehrlichiosis and helps to control the degree of early rickettsemia.

Authors:  M Akkoyunlu; E Fikrig
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

7.  Immunopathology and ehrlichial propagation are regulated by interferon-gamma and interleukin-10 in a murine model of human granulocytic ehrlichiosis.

Authors:  M E Martin; K Caspersen; J S Dumler
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

8.  Pathology, immunohistology, and cytokine responses in early phases of human granulocytic ehrlichiosis in a murine model.

Authors:  M E Martin; J E Bunnell; J S Dumler
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections.

Authors:  H Lepidi; J E Bunnell; M E Martin; J E Madigan; S Stuen; J S Dumler
Journal:  Am J Trop Med Hyg       Date:  2000-01       Impact factor: 2.345

Review 10.  Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms.

Authors:  Xiaoyu Hu; Soumya D Chakravarty; Lionel B Ivashkiv
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

View more
  10 in total

Review 1.  The role of CD8 T lymphocytes in rickettsial infections.

Authors:  David H Walker; J Stephen Dumler
Journal:  Semin Immunopathol       Date:  2015-04-01       Impact factor: 9.623

2.  Anaplasma phagocytophilum, interferon gamma production and Stat1 signaling.

Authors:  Kyoung-Seong Choi; J Stephen Dumler
Journal:  Microbiol Immunol       Date:  2013-03       Impact factor: 1.955

3.  Influence of Genetic Background on Hematologic and Histopathologic Alterations during Acute Granulocytic Anaplasmosis in 129/SvEv and C57BL/6J Mice Lacking Type I and Type II Interferon Signaling.

Authors:  Jennifer L Johns; Marielle L Discipulo; Amanda L Koehne; Kaitlin A Moorhead; Claude M Nagamine
Journal:  Comp Med       Date:  2017-03-01       Impact factor: 0.982

Review 4.  The biological basis of severe outcomes in Anaplasma phagocytophilum infection.

Authors:  J Stephen Dumler
Journal:  FEMS Immunol Med Microbiol       Date:  2011-12-19

5.  Stat1 negatively regulates immune-mediated injury with Anaplasma phagocytophilum infection.

Authors:  Kyoung-Seong Choi; Diana G Scorpio; J Stephen Dumler
Journal:  J Immunol       Date:  2014-10-10       Impact factor: 5.422

6.  Comparison and characterization of granulocyte cell models for Anaplasma phagocytophilum infection.

Authors:  Kristen E Rennoll-Bankert; Sara H Sinclair; Marguerite A Lichay; J Stephen Dumler
Journal:  Pathog Dis       Date:  2013-12-20       Impact factor: 3.166

7.  Cavitary effusion associated with Anaplasma phagocytophilum infection in 2 equids.

Authors:  M M Restifo; D Bedenice; K E Thane; M R Mazan
Journal:  J Vet Intern Med       Date:  2015-02-25       Impact factor: 3.333

8.  Pro-inflammatory immune responses are associated with clinical signs and symptoms of human anaplasmosis.

Authors:  Anna M Schotthoefer; Steven J Schrodi; Jennifer K Meece; Thomas R Fritsche; Sanjay K Shukla
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

9.  Anaplasma phagocytophilum-Related Defects in CD8, NKT, and NK Lymphocyte Cytotoxicity.

Authors:  Diana G Scorpio; Kyoung-Seong Choi; J Stephen Dumler
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

10.  VirB10 vaccination for protection against Anaplasma phagocytophilum.

Authors:  Francy L Crosby; Anna M Lundgren; Carol Hoffman; David W Pascual; Anthony F Barbet
Journal:  BMC Microbiol       Date:  2018-12-18       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.